TickerFacts.

Company research / MYGN

Myriad Genetics Inc (MYGN)

Build a valuation ↗↓ Download CSV

SEC name MYRIAD GENETICS INC · CIK 0000899923 · Nasdaq · In Vitro & In Vivo Diagnostic Substances

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends around Dec 31

For the year ended 2025-12-31, Myriad Genetics Inc reported revenue of $824.50M. Revenue fell 1.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $806.60M.

Key ratios (year ended 2025-12-31)

69.9%
Gross margin
-47.0%
Operating margin
-44.4%
Net margin
-99.4%
Return on year-end equity
-1.6%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-09

Headquarters locality: Salt Lake City · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312020-06-302019-06-302018-06-302017-06-30
Revenue$806.60M$824.50M$837.60M$753.20M$678.40M$690.60M$557.10Mn/a$851.10M$743.70M$728.70M
Cost of Revenue$251.40M$247.90M$252.20M$236.20M$202.00Mn/an/an/an/an/an/a
Gross Profit$555.20M$576.60M$585.40M$517.00M$476.40Mn/an/an/an/an/an/a
R&D Expense$105.80M$106.80M$113.40M$88.70M$85.40M$81.90M$73.30Mn/a$85.90M$70.80M$74.40M
Operating Income-$98.60M-$387.20M-$123.50M-$257.40M-$140.60M-$190.50M-$289.70Mn/a$7.60M$121.90M$44.00M
Depreciation & Amortization$50.20M$53.70M$61.20M$61.90M$52.70M$62.80Mn/a$72.00M$73.00M$54.40M$48.30M
EBITDA-$48.40M-$333.50M-$62.30M-$195.50M-$87.90M-$127.70Mn/an/a$80.60M$176.30M$92.30M
Net Income-$112.60M-$365.90M-$127.30M-$263.30M-$112.00M-$27.20M-$223.60Mn/a$4.60M$133.30M$17.40M
EPS (Diluted)n/a-$3.95-$1.41-$3.18-$1.39-$0.35-$2.99n/a$0.06$1.85$0.25
Total Assets$638.90M$706.60M$1.03B$1.15B$1.20B$1.32B$1.42B$1.40B$1.56B$1.18B$1.21B
Total Liabilities$335.00M$338.60M$326.50M$363.30M$312.90M$352.90M$537.80M$486.40M$473.80M$209.20M$440.90M
Long-Term Debt$120.70M$119.90Mn/an/a$0$0$224.80M$224.40M$233.50M$9.30M$99.10M
Shareholders' Equity$303.90M$368.00M$701.10M$783.20M$885.80M$967.80M$881.00M$918.20M$1.09B$966.10M$768.40M
Cash & Equivalents$115.20M$149.60M$102.40M$132.10M$56.90M$257.40M$117.00M$163.70M$93.20M$110.90M$102.40M
Operating Cash Flow$7.70M$1.80M-$8.70M-$110.90M-$106.30M$18.60Mn/a$60.70M$83.70M$115.90M$106.20M
Capital Expendituresn/an/an/an/a$45.30M$18.00Mn/a$10.20M$8.60M$8.40M$6.10M
Free Cash Flown/an/an/an/a-$151.60M$600.0Kn/a$50.50M$75.10M$107.50M$100.10M
Share Repurchasesn/an/an/an/an/a$0n/a$0$50.00Mn/a$31.60M
Shares Outstanding95.60M93.50M91.30M89.90M81.20M80.00M75.40M74.70M73.50M70.60M68.40M
Weighted Average Diluted Sharesn/a92.60M90.60M82.80M80.60M78.00M74.80Mn/a76.00M72.00M68.80M
EPS (Basic)n/a-$3.95-$1.41-$3.18-$1.39-$0.35-$2.99n/a$0.06$1.92$0.25

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView